Oligodendroglioma Clinical Trials 2024

Oligodendroglioma Clinical Trials 2024

Oligodendroglioma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in oligodendroglioma clinical trials today.

Oligodendroglioma Clinical Trials

Here are the 6 most popular medical studies for oligodendroglioma

Popular filter options for oligodendroglioma trials

AO Clinical Trials

View 28 AO medical studies.

Glioblastoma Clinical Trials

View 22 Glioblastoma medical studies.

IDH Positive Clinical Trials

View 6 IDH positive medical studies.

Oligodendroglioma Clinical Trials With No Placebo

View 30 oligodendroglioma medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to oligodendroglioma

What are the top hospitals conducting oligodendroglioma research?

Advancements in the understanding and treatment of oligodendroglioma, a rare type of brain tumor, are being made by top hospitals across the United States. One such institution making significant strides is Memorial Sloan Kettering Cancer Center in New york City. With six active clinical trials dedicated to this condition and a total of 11 conducted throughout their history, they have been at the forefront since recording their first trial in 2002. In Winston-Salem, North carolina, Wake Forest University Health Sciences is also actively involved in oligodendroglioma research with three ongoing trials and a notable nine completed studies since initiating their first trial in 2004.

Not too far away at Washington University School of Medicine in Saint Louis, Missouri, researchers are working diligently on three active oligodendroglioma trials alongside eight previous investigations which date back to their pioneering efforts starting from 2004. Meanwhile, M D Anderson Cancer Center located in Houston takes pride not only having achieved conducting present-day trio but has also marked its imprint with accomplishing just asmany past experiments dealing with this particular type of brain tumor; it all began for them back then around two decades ago.

Dana Farber Cancer Institute adds itself to this prestigious list as well with three ongoing clinical trials focused on oligodendroglioma along withinvolvement within five similar endeavors dated from year2005 onwards exclusively based out Boston's medical landscape.This collective effort among these renowned hospitals demonstrates commitment towards advancing knowledge about oligodendroglioma and improving outcomes for patients affected by this rare neurological disease that impacts individuals worldwide.

Which are the best cities for oligodendroglioma clinical trials?

The top cities for oligodendroglioma clinical trials are Boston, Houston, and New york. These cities have 9 active trials each that focus on various treatments such as rQNestin, dabrafenib, Proton Beam Radiation Therapy, INCB7839, and Pemigatinib. With a strong presence in research and development, these cities offer individuals with oligodendroglioma access to cutting-edge clinical trials that explore innovative treatment options and potentially contribute to advancements in care.

Which are the top treatments for oligodendroglioma being explored in clinical trials?

Oligodendroglioma, a rare form of brain tumor, is currently being targeted in clinical trials with several promising treatments. A pharmacological study takes the lead with two active trials and 11 all-time oligodendroglioma trials since its introduction in 2003. Another avenue of exploration involves combining cetuximab and bevacizumab through SIACI, showing potential in one ongoing trial that marks its debut on the scene in 2023. Additionally, craniotomy—a surgical procedure—holds promise as another treatment option under investigation with one active trial listed for oligodendroglioma. Finally, retifanlimab shows encouraging results as it enters the field with one ongoing trial following its first listing just last year (2022). As researchers delve deeper into these avenues for treating oligodendroglioma, there is hope for improved outcomes and an increased quality of life for patients facing this challenging diagnosis.

What are the most recent clinical trials for oligodendroglioma?

A multitude of recent clinical trials have emerged, bringing hope and potential advancements for individuals with oligodendroglioma. These trials include a phase 1 study exploring the effectiveness of low-dose OKN-007 administered twice daily, a single-arm trial investigating new treatment options specific to oligodendroglioma, and Phase 1 studies evaluating neural stem cells expressing CRAd-S-pk7 as well as surVaxM in patients who experienced relapse or progression. These groundbreaking endeavors provide promising prospects for improved outcomes in the management of oligodendroglioma.

What oligodendroglioma clinical trials were recently completed?

Recent advancements in oligodendroglioma clinical trials have brought hope for improved treatments. In January 2019, the National Cancer Institute wrapped up a trial investigating LB-100, demonstrating progress in understanding its potential against this complex brain tumor. Additionally, Northwestern University completed a trial in April 2017 examining neural stem cells loaded with an oncolytic adenovirus as a possible therapeutic approach. These milestones highlight ongoing efforts to address the challenges of oligodendroglioma and offer promising avenues for future research and treatment options.